TerminatedEUCTR 2015-000465-31
Cannabidiol in Depression in bipolarity – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in Depression in bipolarity
This historical record does not confirm current site availability.
Historical research recordGermany
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with bipolarity. Other eligibility criteria apply.
- Listed locations
- Germany
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Terminated
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Charité - Universitätsmedizin Berlin
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2015-000465-31
- Official title
Show the full official title
Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Germany
Registry details
Historical country statuses
- Germany — Prematurely Ended
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Charité - Universitätsmedizin Berlin.
Who can participate?
This study is for people with bipolarity. Other eligibility criteria apply.
Is this study still recruiting?
The historical registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Phase 2 Clinical Trial of GH001 in Patients with Bipolarity type II and a Current Major Depressive Episode (GH001-BD-202)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg a...